These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 23375353)

  • 21. Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive.
    Anttila L; Kunz M; Marr J
    Contraception; 2009 Nov; 80(5):445-51. PubMed ID: 19835718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of uterine concentrations of ethinyl estradiol and etonogestrel after use of a contraceptive vaginal ring and an oral contraceptive.
    Roumen FJ; Dieben TO
    Fertil Steril; 2006 Jan; 85(1):57-62. PubMed ID: 16412731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationale for new oral contraceptive dosing.
    Williams JK
    Int J Fertil Womens Med; 2004; 49(1):30-5. PubMed ID: 15038507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombotic risks of oral contraceptives.
    Rott H
    Curr Opin Obstet Gynecol; 2012 Aug; 24(4):235-40. PubMed ID: 22729096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women.
    Sevinsky H; Eley T; Persson A; Garner D; Yones C; Nettles R; Krantz K; Bertz R; Zhang J
    Antivir Ther; 2011; 16(2):149-56. PubMed ID: 21447863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How low can you get?
    Brincat M; Baron YM; Galea R
    Ann N Y Acad Sci; 2003 Nov; 997():158-62. PubMed ID: 14644822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
    Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
    N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oestrogens in oral contraception: considerations for tailoring prescription to women's needs.
    Fruzzetti F; Fidecicchi T; Gambacciani M
    Eur J Contracept Reprod Health Care; 2024 Jun; 29(3):93-102. PubMed ID: 38683756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Low dose oral contraceptives: 30 microg are still used?].
    De Leo V; Caruso S; Scolaro V; Cianci A
    Minerva Ginecol; 2009 Oct; 61(5):453-8. PubMed ID: 19749677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progestin-only contraception and venous thromboembolism.
    Blanco-Molina MA; Lozano M; Cano A; Cristobal I; Pallardo LP; Lete I
    Thromb Res; 2012 May; 129(5):e257-62. PubMed ID: 22425318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. YAZ and the novel progestin drospirenone.
    Mishell DR
    J Reprod Med; 2008 Sep; 53(9 Suppl):721-8. PubMed ID: 18980044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ethinylestradiol in combined hormonal contraceptive has a broader effect on serum proteome compared with estradiol valerate: a randomized controlled trial.
    Kangasniemi MH; Arffman RK; Joenväärä S; Haverinen A; Luiro K; Tohmola T; Renkonen R; Heikinheimo O; Tapanainen JS; Piltonen TT
    Hum Reprod; 2023 Jan; 38(1):89-102. PubMed ID: 36416543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of estrogenic components used for hormonal contraception.
    Stanczyk FZ; Winer SA; Foidart JM; Archer DF
    Contraception; 2024 Feb; 130():110310. PubMed ID: 37863464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical experience of a combined oral contraceptive with very low dose ethinyl estradiol.
    Akerlund M
    Acta Obstet Gynecol Scand Suppl; 1997; 164():63-5. PubMed ID: 9225641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.
    Barditch-Crovo P; Trapnell CB; Ette E; Zacur HA; Coresh J; Rocco LE; Hendrix CW; Flexner C
    Clin Pharmacol Ther; 1999 Apr; 65(4):428-38. PubMed ID: 10223781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database.
    Hasegawa S; Matsui T; Hane Y; Abe J; Hatahira H; Motooka Y; Sasaoka S; Fukuda A; Naganuma M; Hirade K; Takahashi Y; Kinosada Y; Nakamura M
    PLoS One; 2017; 12(7):e0182045. PubMed ID: 28732067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical study of the low dose oral contraceptive novynette].
    Uchikova E; Milchev N
    Akush Ginekol (Sofiia); 2003; 42(4):15-6. PubMed ID: 14577362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters: conventional vs. extended-cycle use.
    Sänger N; Stahlberg S; Manthey T; Mittmann K; Mellinger U; Lange E; Kuhl H; Wiegratz I
    Contraception; 2008 Jun; 77(6):420-5. PubMed ID: 18477491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of a new oral contraceptive containing drospirenone.
    Shulman LP
    J Reprod Med; 2002 Nov; 47(11 Suppl):981-4. PubMed ID: 12497672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17 beta-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol.
    Duijkers IJ; Klipping C; Grob P; Korver T
    Eur J Contracept Reprod Health Care; 2010 Oct; 15(5):314-25. PubMed ID: 20695770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.